The direct cardioprotective, antifibrotic, anti-inflammatory, and diuretic effects with minimal deleterious hemodynamic effects make SGLT2 inhibitors a promising agent to treat ATTR-CA-associated HF. Here, SLC5A2 is linked to hydrops fetalis.